GHP Q3 2021

ghpglobal health & pharma Personalizing Decision-Making for Breast Cancer Treatment DCISionRT is the culmination of ground-breaking technology created by PreludeDx, the California-based breast cancer diagnostics company dedicated to improving treatment and care for patients. Using advanced artificial intelligence andmachine learning, DCISionRT provides personalized results that influence physician decisions regarding the best treatment pathway for individual patients diagnosed with ductal carcinoma in situ (DCIS), also known as Stage 0 breast cancer, enablingmore effective care and alleviating guesswork on healthcare providers when rendering treatment recommendations. Find out more about the science behind DCISionRT and the team leading a revolution in cancer treatment. Q3 2021 Best DCIS Testing Solution 2021: DCISionRT®